In chronic myeloid leukaemia (CML) expression of the chimeric tyrosine kinase, Bcr-Abl, promotes the inappropriate survival of haemopoietic stem cells by a nonautocrine mechanism in the absence of IL-3. Stimulation of glucose uptake appears to play an important role in the suppression of apoptosis by this cytokine in normal haemopoietic cells. To investigate whether the cell survival mechanisms mediated by the oncoprotein and cytokine showed any similarities, we employed a haemopoietic cell line, TonB210, engineered for inducible expression of BcrAbl. Tyrosine kinase expression in cytokine-deprived cells was found to mimic the effect of IL-3 in maintaining a higher V max for hexose uptake. In both IL-3-treated cells and those expressing Bcr-Abl, high rates of hexose uptake were associated with the retention at the cell surface of approximately 80% of the total cellular content of the GLUT1 glucose transporter. In contrast, treatment of Bcr-Abl-expressing cells for 6 h with the Bcr-Abl kinase inhibitor Glivec (10 lM), in the absence of IL-3, led to internalization of approximately 90% of the cell-surface transporters and drastically decreased (4.470.9 (mean7s.e.m., 4)-fold) the V max for hexose uptake, without significant effect on the K m for this process or on the total cellular transporter content. These effects were not the result of any significant loss in cell viability, and preceded the onset of apoptosis caused by inhibition of Bcr-Abl. Both IL-3 treatment and expression of Bcr-Abl led to enhanced phosphorylation of Akt (protein kinase B). The stimulation of transport by IL-3 and Bcr-Abl in TonB210 cells was inhibitable by phosphatidylinositol 3-kinase inhibitors, indicating the involvement of this kinase in the signal transduction pathway. These findings suggest that inhibition of glucose transport plays an important role in the therapeutic action of Glivec, and that the signal transduction pathways involved in transport stimulation by Bcr-Abl may offer novel therapeutic targets for CML.
Introduction
In the haemopoietic system, apoptosis is induced by withdrawal of growth factors such as IL-3 (Koury and Bondurant, 1990; Williams et al., 1990; Heyworth et al., 1992) , whereas in the presence of IL-3 cell survival, proliferation and development is maintained. Disruption of this regulatory phenomenon occurs when the Bcr-Abl oncoprotein, a tyrosine kinase, is expressed in haemopoietic stem cells, leading to development of a stem cell malignancy, chronic myeloid leukaemia (CML). CML progresses through a chronic phase, when progenitor cells are able to differentiate normally, to a blast crisis in which a leukaemic, differentiation-blocked clone expands rapidly in the peripheral blood and bone. The Bcr-Abl protein is the product of a chimeric gene, bcr-abl, that results from a reciprocal translocation of chromosomes 9 and 22 (Shtivelman et al., 1985; Chopra et al., 1999) in haemopoietic stem cells. The aberrant, constitutive tyrosine kinase activity of Bcr-Abl partially suppresses the apoptosis that would otherwise ensue in the absence of IL-3, leading to inappropriate survival and proliferation of the cells at low cytokine concentrations (Chapman et al., 1996; Cambier et al., 1998) . The exact mechanism by which Bcr-Abl induces CML remains to be established: it appears unlikely that autocrine production of IL-3 plays a major role although this conclusion remains controversial (Jiang et al., 1999; Li et al., 2001; Dorsey et al., 2002) . Nonetheless, it is clear that genesis of the bcr-abl oncogene and its protein tyrosine kinase activity is an important initial step in leukaemogenesis.
The maintenance of glucose transport is achieved by expression of glucose transporters in haemopoietic cells. In respect of haemopoietic cells, the glucose transporter GLUT1 has been shown to play a key role in the suppression of apoptosis in several CML cell models (Kan et al., 1994; Bentley et al., 2001 Bentley et al., , 2003 . For example, exposure of the IL-3-dependent mouse premast cell line IC.DP to IL-3, or expression of a temperature-sensitive (ts) form of the viral Abelson protein tyrosine kinase (v-Abl) in these cells, has been shown to result in increased glucose uptake leading to apoptotic suppression (Kan et al., 1994; Bentley et al., 2003) . Expression of a temperature-sensitive form of the Bcr-Abl kinase in the FDCP-mix multipotent haemopoietic cell line had the same outcome (Bentley et al., 2001) . Moreover, it has been shown that constitutive overexpression of GLUT1 likewise significantly retards IL-3-withdrawal-induced apoptosis in FL5.12 cells (Vander Heiden et al., 2001) . The mechanism underlying stimulation of hexose uptake both by v-Abl and by IL-3 was found to involve translocation of GLUT1 from intracellular stores to the cell surface (Kan et al., 1994; Bentley et al., 2003) . In the IL-3-dependent mouse premast cell line IC2.9, such translocation of GLUT1 has been shown to be dependent upon the cytoskeleton and on the activation of phosphatidylinositol 3-kinase (PI 3-kinase) and, probably, the downstream kinase Akt (protein kinase B) (Bentley et al., 2003) . Interestingly, constitutively active Akt has been shown to stimulate glucose uptake and glucose utilization in FL5.12 cells even in the absence of cytokine, and thus may contribute to its ability to promote cell survival .
We have previously reported a similar dependence on PI 3-kinase activity of the stimulation of glucose uptake by ts Bcr-Abl in FDCP-mix cells (Bentley et al., 2001) . However, the mechanism of transport stimulation by this chimeric kinase remains unclear. Further investigation using such cell lines is complicated by the problem of distinguishing the effects of temperature change from those of kinase activation per se, by suboptimal cell growth at the permissive temperature and by poor cell survival at the nonpermissive temperature. Such problems have recently been circumvented by the generation of a novel cell line, TonB210, for conditional expression of Bcr-Abl. This cell line, derived from the IL-3-dependent murine lymphoid cell line BaF3, was engineered to exhibit tightly regulated, tetracycline-dependent expression of Bcr-Abl (Klucher et al., 1998) . In the uninduced state, TonB210 cells undergo rapid apoptosis when deprived of IL-3. However, induction of Bcr-Abl expression by treatment of the cells with the tetracycline analogue doxycyline results in survival in the absence of IL-3.
We have employed the TonB210 cell line to investigate the molecular mechanism of transport regulation by Bcr-Abl tyrosine kinase in the present study. To achieve this, conditional expression of the oncoprotein in these cells has been complemented by use of the drug Glivec (Imatinib, ST1-571) to regulate its activity once expressed. This 2-phenylaminopyrimidine derivative inhibits the catalytic activity of Bcr-Abl by selective binding to an inactive conformation of the kinase (Schindler et al., 2000; Nagar et al., 2002) . In preclinical studies, exposure to Glivec was shown to inhibit the proliferation of Bcr-Abl-expressing cells in vitro, and to retard the growth of Bcr-Abl malignancies in vivo (Druker, 2002) . It has subsequently been used successfully to treat CML patients in the early chronic stage of the disease (Druker, 2002 (Druker, , 2004 . Thus, our aim was to define the downstream effects of Glivec and Bcr-Abl on glucose transport.
Results
Effect of IL-3 and Bcr-Abl expression on 2-deoxy-D-glucose uptake by TonB210 cells Both IL-3 and induction of Bcr-Abl are known to suppress apoptosis and maintain cell viability in TonB210 cells (Klucher et al., 1998) . In a number of other haemopoietic cell lines, the effect of IL-3 on cell viability appears to be mediated, at least in part, via its ability to maintain GLUT1-catalysed glucose uptake (Nefesh et al., 1991; Kan et al., 1994; Berridge et al., 1995; McCoy et al., 1997) . It was therefore of interest to assess whether IL-3 similarly maintained glucose transport in uninduced, IL-3-dependent TonB210 cells, and whether an early effect of Bcr-Abl was to enhance glucose transport in cytokine-deprived cells. To examine these possibilities, noninduced cells were first deprived of the cytokine for 3 h and then incubated in the absence or presence of 10 ng/ml IL-3 for 1 h before measurement of the kinetics of 2-deoxy-D-glucose transport. Figure 1a shows a resultant kinetic plot, representative of three independent experiments. Readdition of IL-3 to cytokine-deprived cells was found to result in a significant 2.170.6 (mean7s.e.m., n ¼ 3)-fold increase in V max without a significant change in the K m for transport (Table 1) . Western blots of whole-cell lysates revealed that this increase in V max was not associated with any change in the total cellular content of GLUT1 (Figure 1b) . To induce expression of Bcr-Abl, TonB210 cells were incubated in medium containing 1 mg/ml doxycycline but lacking IL-3. In preliminary experiments, Western blotting of cell lysates with a polyclonal antibody against c-Abl revealed that expression of the 210 kDa chimeric kinase was detectable after 4 h, reached a maximum after 8 h, and was subsequently maintained at the same level for at least a further 8 h (results not shown). In subsequent studies, TonB210 cells were therefore routinely induced overnight for 16 h prior to subsequent treatments, during which exposure to doxycycline was continued. In contrast to noninduced cells, cells in which Bcr-Abl expression had been induced in this fashion maintained a high rate of hexose uptake in the absence of cytokine, neither the V max nor the K m for 2-deoxy-D-glucose transport differing significantly from the values seen in noninduced cells treated with IL-3 ( Table 1) .
Effect of Glivec treatment on the viability of noninduced, IL-3-dependent and doxycycline-induced TonB210 cells
To examine further the potential role of the Bcr-Abl kinase in transport regulation, the effects of the relatively specific kinase inhibitor Glivec were next examined. Initially, it was important to establish the concentration range over which Glivec exerted Bcr-Ablspecific effects on the viability of the TonB210 cells. To this end, noninduced, IL-3-treated cells and doxycycline-induced, cytokine-deprived cells were incubated with concentrations of the inhibitor ranging from 1 to 100 mM at 371C for 48 h. The numbers of live cells remaining, in comparison to untreated controls, were then determined. Exposure of doxycycline-induced, cytokine-deprived cells to concentrations of Glivec at or above 1 mM was found to result in >90% loss of cell viability (Figure 2a ). In contrast, there was no significant effect of 1 mM Glivec on the viability of noninduced, IL-3-treated cells, and 7974.6% (mean7s.e.m., n ¼ 3) viability was retained even following exposure to 10 mM Glivec (Figure 2 ). These findings were consistent with previous reports on the effects of the inhibitor on Bcr-Abl-positive cells (Druker et al., 1996) , and suggested that at concentrations of up to 10 mM, Glivec abrogated the suppression of apoptosis (in the absence of IL-3) via specific inhibition of the kinase. A concentration of 100 mM Glivec affected the viability of both the Bcr-Abl-induced and the IL-3-dependent cells; this may have been a nonspecific effect of the compound resulting from inhibition of other kinases.
Effect of Bcr-Abl inhibition on the kinetics of 2-deoxy-D-glucose uptake in TonB210 cells
To test the hypothesis that Bcr-Abl activity was responsible for maintenance of hexose transport in doxycycline-induced, cytokine-deprived cells, the effects on transport of short-term (6 h) treatment with Glivec at 371C were next assessed. Preliminary experiments revealed that Glivec inhibited the uptake of 1 mM 2-deoxy-D-glucose in a concentration-dependent manner with an IC 50 of approximately 0.34 mM (Figure 2b ), but in contrast cytokine-dependent cells were unaffected by the inhibitor (Figure 2c ). In subsequent experiments, a Glivec concentration of 10 mM was therefore employed in order to achieve maximal inhibition of transport while minimizing non-Bcr-Abl-specific effects on cell viability ( Figure 2a ). The effects of such treatment on the kinetics of 2-deoxy-D-glucose uptake are shown in Figure 3a , which is representative of four independent experiments. In Bcr-Abl-induced cells, this specific oncoprotein inhibitor was found to result in a 4.470.9 (mean7s.e.m., n ¼ 4)-fold (Po0.05) decrease in V max , without a significant change in the K m for transport (Table 1) . Western blots of whole-cell lysates revealed that this decrease in V max was not associated with any change in the total cellular content of GLUT1 ( Figure 3b) .
A potentially trivial explanation for the effect on hexose transport of treating Bcr-Abl-expressing cells with Glivec for 6 h might have been a simple loss in cell viability. To assess this possibility, the time courses of changes in cell viability, and in the V max for transport, were measured in parallel following exposure of cells to 10 mM Glivec (Figure 4a ). The data from three independent experiments indicated that exposure to Glivec for 6 h resulted in no significant decrease in live cell number ( Figure 4a ). Similarly, FACS analysis for Annexin Vpositive cells (Figure 4b ) showed that the percentage of apoptotic cells in cultures treated with Glivec for 6 h (2372% (mean7s.e.m., n ¼ 3)) was not significantly different from that in untreated cultures (2371% (mean7s.e.m., n ¼ 3)). In contrast, treatment of cells for 6 h with Glivec resulted in a large (9370.7% (mean7s.e.m., n ¼ 3)) and highly significant (Po0.005) Transporter-mediated 2-deoxy-D-glucose uptake was measured over a range of concentrations following the indicated treatments of cells. The kinetic parameters of transport were estimated from the data as described in Materials and methods and are shown as mean+s.e.m. (n). n ¼ number of separate experiments, within which each uptake measurement was performed in triplicate
Bcr-Abl-induced abnormalities in glucose transport K Barnes et al decrease in the V max for 2-deoxy-D-glucose uptake ( Figure 4a ). These results demonstrated that the loss of transport activity seen following treatment of cells with the Bcr-Abl inhibitor did not reflect merely loss of cell viability.
Effects of IL-3, and the activities of Bcr-Abl and PI 3-kinase, on the subcellular distribution of the GLUT1 transporter
We have previously shown, using both immunocytochemistry and photoaffinity labelling, that stimulation of hexose uptake in IC2.9. cells by IL-3 is mediated by translocation of GLUT1 from intracellular stores to the cell surface (Bentley et al., 2003) . To investigate whether a similar mechanism was involved in transport regulation by Bcr-Abl in TonB210 cells, we first used immunofluorescence microscopy to establish the effects of cytokine deprivation and readdition on the subcellular distribution of GLUT1. After withdrawal of IL-3 from noninduced, IL-3-dependent cells for 3 h, the bulk of the transporter (9076% (mean7s.e.m., n ¼ 3)) was observed to be located in the interior of the cell, and little cell surface staining for GLUT1 was apparent ( Figure 5A ). Readdition of the cytokine for 1 h led to a marked decrease in intracellular immunofluorescence and a concomitant redistribution of GLUT1 to the plasma membrane, such that the latter contained 8975% (mean7s.e.m., n ¼ 3) of the total cellular content of the transporter ( Figure 5A ). The maintenance of high rates of hexose uptake in doxycycline-induced TonB210 cells despite withdrawal of IL-3 suggested that the Bcr-Abl kinase might be acting on the subcellular distribution of GLUT1 in a similar fashion to the cytokine. To examine this possibility, immunofluorescence microscopy was again employed. In contrast to cytokine-deprived, noninduced cells, where the bulk of GLUT1 was found to be intracellular ( Figure 5A ), 77715% (mean7s.e.m., n ¼ 3) of the transporter was observed to be located at the plasma membrane in cytokine-deprived cells following induction of Bcr-Abl expression by exposure to (1 mg/ml) doxycycline for 16 h ( Figure 5B ). Treatment of the cells, in the continuing presence of doxycycline, for a further 6 h with 10 mM Glivec induced a substantial redistribution of the transporter, such that 9278% (mean7s.e.m., n ¼ 3) of the total GLUT1 staining became located inside the cells ( Figure 5B ). The extent of this internalization of the transporter paralleled the >90% loss of transport activity seen following inactivation of Bcr-Abl for the same period (Figure 4a) .
Translocation of GLUT1 to the cell surface in IC2.9 cells in response to IL-3 treatment is known to depend upon the activity of the PI 3-kinase pathway (Bentley et al., 2001 ). Bcr-Abl-mediated transformation of cells is likewise associated with activation of PI 3-kinase, although multiple additional signalling pathways are also engaged by Bcr-Abl (Skorski et al., 1997; Hoover et al., 2001) . To examine the involvement of PI 3-kinase in changes in the subcellular distribution of GLUT1, the effects of two potent PI 3-kinase inhibitors were investigated. Inhibitor concentrations were chosen to provide robust inhibition of PI 3-kinase (Bentley et al., 2003) while having no significant effect Figure 4 Effect of Glivec on the V max of 2-deoxy-D-glucose uptake and on cell viability in induced TonB210 cells. (a) Induced, cytokine-deprived cells, expressing Bcr-Abl, were suspended in serum-free medium containing doxycycline (1 mg/ml) and then incubated in the absence or presence of 10 mM Glivec for up to 6 h. At the time points indicated the V max for transporter-mediated uptake of 2-deoxy-D-glucose (') was measured as described in Materials and methods and cell viability was estimated by the Trypan blue exclusion method (). Data shown are expressed relative to untreated cells (100%) and are means7s.d. of triplicate measurements. (b) Induced, cytokine-deprived cells, expressing Bcr-Abl, were suspended in serum-free medium containing doxycycline (1 mg/ml) and then incubated in the absence or presence of 10 mM Glivec for 6 h. Cells were subsequently stained with propidium iodide and Annexin -V-FITC as described the Materials and methods section prior to cytometric analysis. Viable cells are those in the lefthand bottom quadrant, early apoptotic cells are those in the right-hand bottom quadrant, late apoptotic/necrotic cells are in the upper right-hand quadrant and the left-hand upper quadrant represents cell debris. The data shown are representative of three independent experiments on the basal rate of 1 mM 2-deoxy-D-glucose uptake by the TonB210 cells (results not shown). Noninduced, IL-3-dependent TonB210 cells were incubated with the inhibitors for 15 min prior to treatment with or without 10 ng/ml IL-3 for a further hour in the continuing presence of the inhibitors. The effect of 100 nM wortmannin on cells incubated with the cytokine resembled that of cytokine deprivation, in that it led to the transporter being located predominantly in the cell interior, and there was no additional effect of the inhibitor on cytokine-deprived cells ( Figure 5B ). In contrast to these findings, incubation of doxycyclineinduced TonB210 cells for the same period (1 h 15 min) with either 100 nM wortmannin (data not shown), 500 nM wortmannin or 100 mM LY294002 had no effect on the plasma membrane localization of GLUT1 ( Figure 5B ). The presence of these inhibitors during the last 1 h 15 min of a 6-h incubation of the cells with 10 mM Glivec similarly had no effect on the predominantly intracellular localization of GLUT1 induced by inactivation of Bcr-Abl ( Figure 5B ). However, if the period of incubation with these PI 3-kinase inhibitors was extended to 6 h, their effect resembled Glivectreated control cells in that the transporter was located in the cell interior, irrespective of whether 10 mM Glivec was included in the incubation medium ( Figure 5B ). Bcr-Abl-induced abnormalities in glucose transport K Barnes et al
Effect of kinase inhibitors on 1 mM 2-deoxy-D-glucose uptake
To assess further the possible involvement of PI 3-kinase in the stimulation of glucose transport by IL-3 or BcrAbl, the effects of the PI-3 kinase inhibitors were investigated using the same incubation conditions as for the GLUT1 subcellular distribution experiments described above. Exposure of noninduced, IL-3-dependent cells to LY294002 at concentrations of either 10 or 100 mM for 1 h 15 min drastically inhibited the stimulation of hexose uptake by IL-3 but had only a minor effect on the basal rate of uptake (Figure 6a ). The potent PI 3-kinase inhibitor wortmannin, when employed at concentrations of either 100 or 500 nM, similarly decreased the rate of transport in IL-3-stimulated cells to basal levels (results not shown). In contrast, after an incubation period of 1 h 15 min, 500 nM wortmannin effected a small increase and 100 mM LY294002 had no effect on glucose uptake in TonB210 cells in which BcrAbl had been activated by incubation with doxycycline ( Figure 6b ). These PI 3-kinase inhibitors similarly had no significant effect on the basal rate of uptake seen in induced cells that had been treated with Glivec to inactivate Bcr-Abl (Figure 6b ). These findings were consistent with the lack of effect of a similarly short period of exposure to the inhibitors on the subcellular distribution of GLUT1 in doxycycline-stimulated cells ( Figure 5B ). However, consistent with the internalization of GLUT1 seen in doxycyline-treated cells following a longer exposure to the PI-3-kinase inhibitors ( Figure 5B ), exposure of Bcr-Abl-induced cells to wortmannin and LY294002 for 6 h resulted in the reduction of hexose uptake rates to basal levels, that is, the rates of uptake were equivalent to those seen in Glivec-treated cells exposed to the PI 3-kinase inhibitors (Figure 6c ). In addition to a requirement for PI 3-kinase activity, stimulation of glucose transport and translocation of GLUT1 to the cell surface in IC2.9 cells in response to IL-3 treatment appears to involve the downstream serine/threonine kinase Akt (Bentley et al., 2001 ). BcrAbl-mediated transformation of cells is likewise associated with activation of these kinases, although multiple additional signalling pathways are also engaged by Bcr-Abl (Skorski et al., 1997; Hoover et al., 2001) . Moreover, constitutively activated Akt has been reported to facilitate the development of growth factor independence and leukaemogenesis in haemopoietic progenitor cells (Karnauskas et al., 2003) . To investigate Figure 6 The effects of PI 3-kinase inhibitors on 2-deoxy-Dglucose transport in IL-3-dependent and in IL-3-independent, BcrAbl-expressing TonB210 cells. (a) Noninduced, IL-3-dependent cells were depleted of IL-3 by washing over a period of 3 h then incubated for a further 1 h with or without 10 ng/ml IL-3 in the presence or absence of LY294002 at the concentrations indicated before measurement of 2-deoxy-D-glucose uptake. The inhibitor was added 15 min prior to addition of the cytokine. (b) and (c) Cytokine-deprived cells, incubated with doxycycline (1 mg/ml) to induce expression of Bcr-Abl, were incubated with or without 10 mM Glivec for 6 h before measurement of 2-deoxy-D-glucose uptake. The inhibitors wortmannin or LY294002 were included, for the periods indicated, during the latter part of this incubation. Results shown are the mean7s.d. of triplicate measurements of the uptake of 1 mM 2-deoxy-D-glucose and are representative of three independent experiments. Asterisks (*) indicate significant reduction by PI 3-kinase inhibitors in the extents of 2-deoxy-D-glucose transport stimulation by IL-3 and Bcr-Abl in (a) and (c), respectively (Po0.05). Asterisks (**) indicate significant increase (Po0.05) in glucose uptake in cells treated with 500 nM wortmannin the possibility that Akt is involved in the regulation of hexose transport by IL-3 and/or Bcr-Abl activity in TonB210 cells, the effects of these stimuli on the phosphorylation states of Akt were evaluated. This was achieved by scanning densitometry of Western blots of cell lysates stained with antibodies specific for either phospho(Ser 473 )Akt or phospho(Thr 308 )Akt. Addition of IL-3 (10 ng/ml) for 5 min to cells that had been deprived of the cytokine for 3 h was found to result in a 1072-fold (mean7s.e.m., n ¼ 3) increase in phosphorylation of Akt on Ser 473 (Figure 7a ). However, in the presence of 100 mM LY294002, added 15 min prior to the cytokine, phosphorylation remained at the basal level following exposure to IL-3 (Figure 7a) . To examine the effect of Bcr-Abl on the activation state of Akt, cells from the same batch were induced with 1 mg/ml doxycycline for 16 h in the absence of IL-3, followed by further incubation for 6 h with or without 10 mM Glivec. Cytokine-deprived, Bcr-Abl-induced cells that had not been treated with Glivec showed a level of Akt Ser 473 phosphorylation comparable with that seen in cytokine-treated, noninduced cells (Figure 7) . However, Glivec treatment of the doxycycline-induced cells caused 3.070.5 (mean7s.e.m., n ¼ 3)-fold and 3.570.8 (mean7s.e.m., n ¼ 3)-fold decreases in Akt phosphorylation at Ser 473 ( Figure 7a ) and Thr 308 (Figure 7b ), respectively. In contrast to noninduced, cytokine-dependent cells, the phosphorylation state of Akt in TonB210 cells, expressing Bcr-Abl, was not reduced to basal levels by exposure to 100 mM LY294002 unless the incubation period of cells with the inhibitor was 6 h or Glivec was also present in the incubation medium (Figure 7a ). Equal loading of the protein samples was demonstrated by stripping and reprobing the blots with antibodies reactive against both phosphorylated and nonphosphorylated forms of Akt (total AKT) and then with antibodies against tubulin (Figure 7 ).
Discussion
Expression of the bcr-abl gene in cytokine-dependent cells is well known to result in varying degrees of growth factorindependent survival, proliferation and resistance to apoptosis induced by DNA damage (Pierce et al., 1998; Hoover et al., 2001; Kansara and Berridge, 2004) . Bcr-Abl expression represents a key initial step in leukaemogenesis in CML (Chapman et al., 1996) . We have previously shown that a rapid consequence of IL-3 withdrawal from cytokine-dependent cells, which precedes the commitment to apoptosis by several hours, is a decreased rate of glucose uptake, and that apoptosis can be suppressed, at least in part, by the provision of alternative energy sources such as glutamine (Kan et al., 1994) . Figure 7 Effect of IL-3 and of Bcr-Abl activity on the phosphorylation of Akt in TonB210 cells. Noninduced, IL-3-dependent cells were washed for 3 h at 371C to remove IL-3-conditioned culture medium then incubated for 15 min with or without LY294002 and for a further 5 min in the presence or absence of 10 ng/ml IL-3 as indicated. Induced, cytokine-deprived cells, expressing Bcr-Abl, were suspended in serum-free medium containing doxycycline (1 mg/ml) and then either left untreated or incubated with 10 mM Glivec for a further 6 h as indicated, in the presence or absence of 100 mM LY294002 for the times indicated. Representative Western blots of protein samples from equal amounts of cell lysates from (a: left panel) and (b: right panel) were then stained with antibodies against the proteins indicated. The mobilities of marker proteins of known molecular mass are shown on the left
In the present study, we have used the TonB210 cell line, in which Bcr-Abl expression can be rapidly regulated using tetracycline analogues, in order to define the immediate effects of this tyrosine kinase on transport regulation. Induction of kinase expression in cytokinedeprived cells was found to mimic the effect of IL-3 addition in that it resulted in an increase in the V max for 2-deoxy-D-glucose uptake without significant change in the apparent affinity for substrate. The specific role of the kinase in transport stimulation was confirmed by the effect of Glivec treatment, which caused a dramatic decrease in the V max for transport in induced Bcr-Ablexpressing cells, but not in cytokine-dependent cells. The effects of IL-3 addition/withdrawal and Bcr-Abl expression/inhibition on the V max for hexose transport correlated with alterations in the distribution of GLUT1 glucose transporters between the cell interior and the plasma membrane. These findings suggest that both the cytokine and the oncoprotein regulate the rate of cellular glucose uptake primarily by controlling the cell surface concentration of GLUT1.
Transformation of haemopoietic cells by Bcr-Abl expression has been linked to multiple signalling pathways, including the PI 3-kinase/Akt, the Ras and the STAT5 pathways, which appear to contribute to different aspects of the transformed phenotype (Hoover et al., 2001) . For example, the survival of IL-3-dependent BaF3 cells following cytokine withdrawal can be greatly enhanced by expression of a constitutively active form of Akt, although this kinase does not mimic the effect of Bcr-Abl on cell proliferation or resistance to DNA damage-induced apoptosis (Hoover et al., 2001) . Similarly, v-Abl-induced survival of IC.DP cells deprived of IL-3 was found to be inhibitable either by exposure of cells to the PI 3-kinase inhibitor LY294002 or by expression of a dominant-negative form of Akt (Tang et al., 2000) . More recently it was shown that in primary CML progenitor cells, Bcr-Abl-induced PI 3-kinase activity was suppressed following inhibition of the oncoprotein by Glivec and that proliferation of these cells was reduced by the PI-3 kinase inhibitors, wortmannin and LY294002 (Marley et al., 2004) . The signalling pathways involved in regulation of transport in haemopoietic cells remain to be completely characterized. However, we have previously shown that stimulation of hexose uptake by IL-3 receptor ligation in IC2.9 cells requires the PI 3-kinase pathway and that the downstream target kinase Akt is likely also to be involved (Bentley et al., 2003) . In the present study, Glivec treatment of TonB210 cells expressing Bcr-Abl was found to result in decreased phosphorylation of Akt, a finding consistent with the involvement of the kinase in transport regulation. PI 3-kinase inhibitors prevented stimulation, by IL-3 in noninduced cells and by activated Bcr-Abl in induced cells, of transport, translocation of GLUT1 to the cell surface and phosphorylation of Akt. These findings suggest that Bcr-Abl can activate Akt in TonB210 cells, via a signalling pathway that includes PI 3-kinase. They support and extend the results of our previous study using the FDCP-mix tsBcr-Abl cell line, in which transport stimulation by the oncoprotein was inhibitable by LY294002 (Bentley et al., 2001) . The difference in time of exposure to inhibitor required for an effect on hexose transport in experiments involving IL-3 (1 h 15 min) and activated Bcr-Abl (6 h), respectively, probably reflects differences in the rates of exocytotic insertion into, and endocytic retrieval from, the plasma membrane of GLUT1-containing vesicles, respectively. Thus in the case of experiments involving IL-3, the inhibitors were included prior to stimulation of transporter exocytosis. This was not practical in the case of doxycycline induction of Bcr-Abl expression, which required a much longer period (16 h), and so the effects of subsequent treatment with PI 3-kinase inhibitors would have reflected the rate of transporter endocyto sis following inhibition of exocytosis. Similar explanations could account for the differing time courses of the effects of PI 3-kinase inhibitors on Akt phosphorylation states in the two situations. At any rate, our findings suggest that trafficking of the GLUT1 protein to the inside of the cell is one of the important events following inactivation of Bcr-Abl by Glivec or inhibition of PI 3-kinase by wortmannin or LY294002, and which eventually leads to apoptosis of Bcr-Abl-expressing TonB210 cells.
Previously, Boren et al. (2001) and more recently Gottschalk et al. (2004) showed that inhibition by Glivec of Bcr-Abl activity in K562 cells, derived from a patient with CML-related blast crisis, caused significant changes in cellular glucose metabolism. In the present study, using the TonB210 cell line as a CML model, we have shown that a rapid response to inhibition of the kinase with Glivec is a dramatic loss of hexose uptake activity, caused by relocation of cell surface glucose transporters to the cell interior. Given our previous findings concerning the role of transport regulation in the suppression of apoptosis by IL-3 and v-Abl, it is likely that downregulation of transport plays a significant role in the therapeutic effect of the Glivec. The signal transduction pathway(s) linking the kinase and transport may therefore offer novel chemotherapeutic targets for CML of particular utility in cases of acquired Glivec resistance (Azam et al., 2003) .
Materials and methods

Cell culture
TonB210 cells were routinely cultured as described in Klucher et al. (1998) . Cells were grown to confluence in 25 cm 2 flasks at 371C under 5% (v/v) CO 2 in RPMI 1640 medium (RPMI: GIBCO, LifeTechnologies, UK), supplemented with 2 mM L-glutamine, 10% (v/v) heat-inactivated foetal calf serum and 7.5% (v/v) X63-Ag 653 cell-conditioned medium containing IL-3. Cells cultured under these conditions were designated noninduced, IL-3-dependent cells. Bcr-Abl expression was induced by treatment with doxycycline (1 mg/ml) in the absence of IL-3. Cells cultured under these conditions were designated induced cells.
2-Deoxy-D-glucose transport assay
TonB210 cells were assayed for hexose uptake using a modification of the protocol described in Bentley et al. 2003) . Noninduced, IL-3-dependent cells were taken from mid-log phase and washed three times over a period of 3 h at 371C in RPMI containing 25 mM HEPES (RPMI/ HEPES). They were then suspended to 1 Â 10 7 cells per millilitre in RPMI/HEPES prior to incubation with the appropriate concentration of IL-3 and/or inhibitor for the times indicated. Induced TonB210 cells expressing Bcr-Abl were washed twice to remove serum and suspended to 1 Â 10 7 cells per ml in RPMI/HEPES containing doxycycline (1 mg/ml) prior to incubation with the inhibitor, Glivec, for the times indicated. Before subsequent sugar uptake measurements, cells were washed twice in Krebs-Ringer/HEPES buffer (KRH buffer; 136 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl 2 , 1.25 mM MgSO 4 , 10 mM HEPES, pH 7.4) to remove glucose. Transport experiments were performed on 50 ml samples of cells in KRH buffer at a concentration of approx. 1 Â 10 7 cells per millilitre. Uptake of 2-deoxy-D-glucose (0.1-10 mM, containing 2 mCi/ml [ 3 H]-2-deoxy-D-glucose) (Amersham Life Science Ltd., Buckinghamshire, UK) was measured over a period of 1 min at 371C, during which period the rate of hexose transport had previously been shown to be linear (data not shown). Transport was terminated by addition of ice-cold KRH buffer containing 200 mM phloretin, and centrifugation through a layer of mixed oils consisting of Dow Corning 550 silicone fluid (BDH, Poole, UK) and dinonylphthalate (Fisher Scientific, Loughborough, UK) (1 : 1 by volume). The oil layer was washed three times, aspirated and the resultant cell pellet was solubilized in 100 ml 1 M NaOH for 1 h. Emulsifier safe liquid scintillant (Packard Bioscience BV, Groningen, The Netherlands) was then added and the radioactivity determined 16 h later. Transportermediated uptake rates were calculated by subtracting nonspecific uptake measured in the presence of 20 mM cytochalasin B from the initial rates.
Statistical analysis
The kinetic parameters of transport were estimated from the data by nonlinear curve-fitting to the Michaelis-Menten equation using Origin version 7 (Origin Lab Corporation).
Where significance values are indicated the two-tailed unpaired Student's t-test was used to determine the statistical significance of results.
Cell viability assays and cytometric analysis
The viability of induced and noninduced cells following treatment with or without Glivec (Imatinib, ST1-571; a gift from Novartis-Pharma, AG Basel, Switzerland) was determined using trypan blue exclusion as previously described (Owen et al., 1993; Bentley et al., 2003) . The percentage of cells undergoing apoptosis was determined quantitatively using Annexin V-FITC and propidium iodide labelling procedure (Bentley et al., 2003) (BD Biosciences, Cowley, Oxford, UK) staining and flow cytometry. Cells (1 Â 10 6 /ml) were washed twice in binding buffer (10 mM HEPES, pH 7.4, containing 140 mM NaCl and 2.5 mM CaCl 2 ) at 41C. After addition of 5 ml Annexin V-FITC, 100 ml (1 Â 10 5 cells) of the cell suspension was incubated in the dark at 221C for 15 min. Binding buffer (300 ml) containing propidium iodide (20 mg/ml) (Sigma-Aldrich, Poole, Dorset, UK) was added and the cells analysed by flow cytometry using a Becton Dickinson FACScalibur system and CellQuest software.
Western blotting and immunocytochemistry
Cells (1 Â 10 7 per ml) were washed 1 Â in PBS, pH 7.4, supplemented with 1 mM Na 3 VO 3 , 2 mM EDTA, 1 mM NaF, 1 mM Na 4 P0 7 and a cocktail of protease inhibitors for use with mammalian cell and tissue extracts (Sigma-Aldrich, Poole, Dorset, UK). They were then lysed in 200 ml SDS-PAGE sample buffer. For Western blotting, proteins were subjected to electrophoresis on 10% (w/v) polyacrylamide/SDS gels and then transferred to nitrocellulose membranes (Bentley et al., 2003) . Blots were probed overnight at 41C with affinitypurified rabbit antipeptide antibodies to human c-Abl (raised against residues 728-739), to all forms of mouse Akt (raised against residues 466-479), or specific to mouse Akt phosphorylated at Thr 308 or Ser 473 , respectively (Cell Signaling Technologyt, New England Biolabs, Hitchin, Hertfordshire, UK). Affinity-purified rabbit antibodies (0.2 mg/ml) raised against a synthetic peptide corresponding to the C-terminal region of GLUT1 (residues 477-492) (Davies et al., 1990) , and mouse monoclonal antibodies against tubulin (Sigma-Aldrich, Poole, Dorset, UK) were also employed. Horseradish peroxidase conjugates of goat anti-rabbit or anti-mouse IgG (1/50 000; Jackson ImmunoResearch Laboratories, Stratech Scientific Ltd, Soham, Cambridgeshire, UK) were subsequently applied as appropriate for 1 h. The antigens were then visualized by addition of enhanced chemiluminescence detection reagents (Supersignal s chemiluminescent substrate, Pierce Chemical Company, UK). Staining intensity was quantified using a Bio-Rad Fluor-S gel documentation system and Multianalyst software.
Cells were prepared for immunofluorescence microscopy on polylysine-coated microscope slides (BDH, Poole, UK) as previously described (Bentley et al., 2003) . Noninduced, IL-3-dependent cells were depleted of cytokine and then treated with or without recombinant IL-3 as described for the 2-deoxy-D-glucose transport assays. Similarly, induced TonB210 cells expressing Bcr-Abl were washed prior to incubation with or without the inhibitor, Glivec, as described for the transport assays. Cells were stained for GLUT1 using the affinitypurified rabbit antibodies (20 mg/ml) described above, followed by FITC-conjugated goat anti-rabbit IgG. For imaging, 20 optical sections were captured at 0.2 mm intervals with a Delta Vision s system (Applied Precision, Issaquah, WA, USA) comprising an Olympus IX70 microscope linked to a CCD camera, and processed using the manufacturer's deconvolution software. Image J (http://www.rsb.info.nih.gov/ij) was used to quantify cell surface fluorescence from images captured from three separate experiments.
